Has Gerald Milan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,012 in general payments to Gerald Milan, MD across 340 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gerald Milan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gerald Milan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gerald Milan, MD

Nephrology · Dover, DENPI 1801875992

Payments from drug & device makers

$16,012in general payments, 2019–2025

Across 340 payments — averaging $47.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$5K
AstraZeneca$3K
Fresenius USA Marketing, Inc.$1K
Baxter Healthcare$862
Vifor Pharma, Inc.$674
Akebia Therapeutics Inc$597
plus $5K from 36 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	37	$4,900
AstraZeneca(2 entities)	43	$2,956
Fresenius USA Marketing, Inc.	48	$1,081
Baxter Healthcare	1	$862
Vifor Pharma, Inc.	21	$674
Akebia Therapeutics Inc	30	$597
Mallinckrodt Hospital Products Inc.	11	$365
Ardelyx, Inc.	13	$358
Otsuka America Pharmaceutical, Inc.	14	$352
Alnylam Pharmaceuticals Inc.	1	$305
Aurinia Pharma U.S., Inc.	12	$304
Vifor (international) Ltd.	1	$300
ZOLL Medical Corporation	1	$300
Bayer	14	$277
Travere Therapeutics, Inc.	15	$230
Tersera Therapeutics LLC	1	$225
Melinta Therapeutics, LLC	1	$215
Novartis	8	$186
Lilly USA, LLC	5	$135
Calliditas Therapeutics US Inc.	6	$123
Boehringer Ingelheim	6	$113
OPKO Pharmaceuticals, LLC	6	$110
ANI Pharmaceuticals, Inc.	4	$102
Kyowa Kirin, Inc.	4	$96
Sanofi	4	$95
AbbVie	1	$93
Takeda Pharmaceuticals U.S.A., Inc.	4	$88
GSK	5	$85
Shield Therapeutics Inc	2	$77
Mallinckrodt Enterprises LLC	2	$48
Xeris Pharmaceuticals, Inc.	2	$48
Amicus Therapeutics, Inc.	2	$48
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$40
Novo Nordisk	2	$35
Biomerieux Inc	2	$34
AMAG Pharmaceuticals, Inc.	2	$30
Scpharmaceuticals Inc.	2	$30
Mozarc Medical US LLC	1	$26
Angiodynamics, Inc.	1	$23
E.r. Squibb & Sons, L.L.C.	1	$18
Shire North American Group Inc	1	$16
Chiesi USA, Inc.	1	$12

How this compares

$16,012 in reported general payments places this provider in the 90th percentile of 49 nephrology providers in Delaware.

See all nephrology providers in Delaware →

Medicare billing

Part B allowed, 2024

$255,722

Medicare patients

531

Services billed

2,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Dover

See the full list for Delaware →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →